Nuclear β-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells by Uchino, Masahiro et al.
RESEARCH ARTICLE Open Access
Nuclear b-catenin and CD44 upregulation
characterize invasive cell populations in
non-aggressive MCF-7 breast cancer cells
Masahiro Uchino
1*, Hiroko Kojima
1,3, Kenta Wada
1,4, Mika Imada
2,5, Fumitoshi Onoda
2, Hiroyuki Satofuka
1,
Takahiko Utsugi
1, Yasufumi Murakami
1,2
Abstract
Background: In breast cancer cells, the metastatic cell state is strongly correlated to epithelial-to-mesenchymal
transition (EMT) and the CD44
+/CD24
- stem cell phenotype. However, the MCF-7 cell line, which has a luminal
epithelial-like phenotype and lacks a CD44
+/CD24
- subpopulation, has rare cell populations with higher Matrigel
invasive ability. Thus, what are the potentially important differences between invasive and non-invasive breast
cancer cells, and are the differences related to EMT or CD44/CD24 expression?
Methods: Throughout the sequential selection process using Matrigel, we obtained MCF-7-14 cells of opposite
migratory and invasive capabilities from MCF-7 cells. Comparative analysis of epithelial and mesenchymal marker
expression was performed between parental MCF-7, selected MCF-7-14, and aggressive mesenchymal MDA-MB-231
cells. Furthermore, using microarray expression profiles of these cells, we selected differentially expressed genes for
their invasive potential, and performed pathway and network analysis to identify a set of interesting genes, which
were evaluated by RT-PCR, flow cytometry or function-blocking antibody treatment.
Results: MCF-7-14 cells had enhanced migratory and invasive ability compared with MCF-7 cells. Although MCF-7-
14 cells, similar to MCF-7 cells, expressed E-cadherin but neither vimentin nor fibronectin, b-catenin was expressed
not only on the cell membrane but also in the nucleus. Furthermore, using gene expression profiles of MCF-7,
MCF-7-14 and MDA-MB-231 cells, we demonstrated that MCF-7-14 cells have alterations in signaling pathways
regulating cell migration and identified a set of genes (PIK3R1, SOCS2, BMP7, CD44 and CD24). Interestingly, MCF-7-
14 and its invasive clone CL6 cells displayed increased CD44 expression and downregulated CD24 expression
compared with MCF-7 cells. Anti-CD44 antibody treatment significantly decreased cell migration and invasion in
both MCF-7-14 and MCF-7-14 CL6 cells as well as MDA-MB-231 cells.
Conclusions: MCF-7-14 cells are a novel model for breast cancer metastasis without requiring constitutive EMT
and are categorized as a “metastable phenotype”, which can be distinguished from both epithelial and
mesenchymal cells. The alterations and characteristics of MCF-7-14 cells, especially nuclear b-catenin and CD44
upregulation, may characterize invasive cell populations in breast cancer.
Background
Patients with breast cancer are at risk of metastasis
throughout their lifetime because of the heterogeneous
nature of breast cancer metastasis. Recent studies focus-
ing on the early steps in the metastatic cascade, such as
epithelial-to-mesenchymal transition (EMT) and altered
cell adhesion and motility, have demonstrated that
aggressive cancer progression is correlated with the loss
of epithelial characteristics and the gain of a migratory
and mesenchymal phenotype [1]. In fact, the highly
aggressive breast cancer cell line MDA-MB-231 exhibits
mesenchymal-type behavior, whereas non-aggressive
breast cancer cell line MCF-7 has a luminal epithelial-
like phenotype [2,3].
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a solid tumor including breast cancer is comprised of
heterogeneous cells in terms of their invasive and meta-
static potential, as suggested by in vivo metastasis mod-
els [4] and an in vitro selection process using Matrigel
[5,6]. Tumor heterogeneity has led to the “cancer stem
cell hypothesis”. Cancer stem cells share common char-
acteristics with normal stem cells: ability to self-renew,
differentiate, acquire drug resistance, survive anchorage-
independently, and migrate. Furthermore, overlapping
sets of molecules and pathways regulate both stem cell
migration and cancer metastasis; therefore, cancer stem
cells are assumed to contribute to metastasis as well
as tumorigenesis [7]. In human breast tumors, the
CD44
+/CD24
-/low phenotype has been reported to have
stem cell properties [8]. Cell lines with high CD44
+/
CD24
- cell numbers were basal/mesenchymal or myoe-
pithelial types and more invasive than other cell lines. In
contrast, non-aggressive epithelial MCF-7 cells lack a
CD44
+/CD24
- subpopulation. Among CD44
+/CD24
--
positive cell lines, MDA-MB-231 has the unique prop-
erty of expressing a broad range of genes that favor
bone and lung metastasis [9]. Although there remains a
need to determine whether CD44
+/CD24
-/low cells are
true breast cancer stem cells across all the various breast
cancer subtypes, there seems to be a connection
between EMT and CD44/CD24 expression in the
mechanisms of breast cancer invasion and metastasis.
Indeed, induction of EMT results in the acquisition of
the CD44
high/CD24
low phenotype in immortalized
human mammary epithelial cells [10].
In the current study, we demonstrated that non-
aggressive epithelial MCF-7 cells had rare cell popula-
tions with higher Matrigel invasive ability. Throughout
the sequential selection process using Matrigel, we
obtained MCF-7-14 cells of opposite migratory and
invasive capabilities from MCF-7 cells. Thus, what are
the potentially important differences between invasive
and non-invasive breast cancer cells, and are the differ-
ences related to EMT or CD44/CD24 expression? To
answer these questions, comparative analysis of epithe-
lial and mesenchymal marker expression was performed
between MCF-7, MCF-7-14, and MDA-MB-231 cells.
Furthermore, using microarray expression profiles of
these cells, we selected differentially regulated genes for
their invasive potential and performed pathway and net-
work analysis to better characterize invasive cell popula-
tions in breast cancer.
Methods
Cell culture
Human breast cancer cell line MCF-7 was obtained
from the Institute of Development, Aging and Cancer,
Tohoku University. MDA-MB-231 was purchased from
the American Type Culture Collection. Both cell lines
were maintained in RPMI 1640 (Sigma-Aldrich, St.
Louis, MO) containing 10% fetal bovine serum (FBS)
and an antibiotic-antimycotic.
In vitro sequential selection of invasive populations from
MCF-7 cells
BD BioCoat Matrigel Invasion Chambers (for a 6-well
plate; BD Biosciences, San Jose, CA) were used to select
invasive populations from MCF-7 cells. MCF-7 cell sus-
pension (4 × 10
5 cells/well) in serum-free RPMI1640
was seeded into the upper chamber. After 60 hours’ cul-
tivation, cells that migrated through the membrane
(named MCF-7-1) were harvested by trypsinization, pro-
liferated on a dish, and then reseeded in a Matrigel
Invasion Chamber. The cycle was repeated 14 times,
and finally MCF-7-14 cells were obtained. In each cycle,
invading cells on the underside of the chamber were
fixed with 10% formalin-neutralized buffer, stained with
0.1% crystal violet, and imaged through a microscope
(Axiovert 200M; Carl Zeiss, Jena, Germany) with a CCD
camera (AxioCam; Carl Zeiss).
Cell proliferation assay
MCF-7 and MCF-7-14 cells (5 × 10
3 cells/well) were
seeded into 96-well plates and cultured. The cells were
counted at 24, 48, 72 and 96 h with a Cell Counting
Kit-8 (MTT assay; Wako Pure Chemical Industries,
Osaka, Japan).
Western blotting
Cell protein lysates were prepared from confluent cell cul-
tures of MCF-7 and MCF-7-14 cells, subjected to SDS-
PAGE, and transferred to PVDF membranes. The mem-
branes were blocked (5% skim milk) and incubated with
rat anti-human epidermal growth factor receptor 2, HER-2
(GeneTex, Irvine, CA) and mouse anti-estrogen receptor
alpha, ER-a (Stressgen/Assay Designs, Ann Arbor, MI)
monoclonal antibodies (mAbs), followed by the corre-
sponding HRP-conjugated secondary antibody (GE
Healthcare, Piscataway, NJ). Antibody complexes were
detected with the ECL detection system (GE Healthcare).
In vitro wound healing assay
Migratory abilities of MCF-7 and MCF-7-14 cells were
measured using the in vitro wound healing assay. Cells
were plated on 10-cm culture dishes and grown to 100%
confluence. Wounds were created by scraping mono-
layer cells with a sterile pipette tip. At 0, 24, 48, 72 and
96 h after the creation of wounds, three different areas
were imaged through an Axiovert 200 M. Wound dis-
tances were measured at each time point and expressed
as the average percent of wound closure by comparing
the zero time.
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Animal experiments were performed in accordance with
the Guidelines of the Japanese Government for the Care
and Use of Laboratory Animals and approved by the
Institutional Animal Care and Use Committee at Tokyo
University of Science and the Ethics Committee of Bio
Matrix Research Inc. MCF-7 and MCF-7-14 cells were
transfected with pEGFP-C1 (encoding the enhanced
green fluorescence protein, EGFP; Clontech Labora-
tories, Mountain View, CA) using Fugene 6 Transfection
Reagent (Roche, Basel, Switzerland) in serum-free med-
ium. MCF-7 and MCF-7-14 cells stably transfected with
pEGFP-C1 (named MCF-7-EGFP and MCF-7-14-EGFP,
respectively) were selected by G418 treatment (500 μg/
ml) for 3 weeks. Suspensions of MCF-7-EGFP and
MCF-7-14-EGFP cells (1 × 10
6 cells/50 μl) were mixed
with the same volume of Matrigel, and injected into the
fourth mammary fat pad of 10-week-old female BALB/
cJ/nu/nu mice.
In vivo and ex vivo imaging of EGFP-labeled breast cancer
cells
At 4, 8 and 12 weeks after implantation of MCF-7-EGFP
and MCF-7-14-EGFP cells, mice were sacrificed and
scanned by a luminescence/fluorescence imaging analy-
zer (LAS3000; Fujifilm, Tokyo, Japan) to detect meta-
static lesions. Ex vivo fluorescence imaging was also
performed on necropsy samples.
Histology and immunohistochemistry
Xenografts and metastatic lesions were rapidly frozen,
and 6 μm thick sections were cut on a cryostat. The sec-
tions were analyzed by hematoxylin/eosin (HE) and
methyl green pyronin (MGP) staining, or unstained sec-
tions were analyzed for EGFP fluorescence. For immu-
nostaining epithelial and mesenchymal markers, mouse
anti-cytokeratin (CK) 19 (A53-B/A2; 1:50 dilution; Santa
Cruz Biotechnology, Santa Cruz, CA), anti-E-cadherin
(67A4; 1:25; Santa Cruz Biotechnology) and anti-vimen-
tin (V9; 1:150; Dako, Glostrup, Denmark) mAbs were
used. Briefly, frozen sections were treated with 3% H2O2
for 10 min and 5% skim milk in Tris-buffered saline
with 0.2% Triton-X for 1 h. Primary antibodies were
applied for 1 h at room temperature. Subsequently, the
sections were incubated with Simple Stain Mouse MAX
PO (Nichirei Biosciences, Tokyo, Japan) or Alexa Fluor
488-conjugated goat anti-mouse IgG (1:200; Molecular
Probes, Invitrogen, Carlsbad, CA) at room temperature.
Diaminobenzidine (DAB) with 0.1% H2O2 (Dako) was
used as the final chromogen and hematoxylin for
nuclear counterstaining in immunohistochemistry. In
immunofluorescence, cell nuclei were counterstained
with 4′, 6-diamidino-2-phenylindole (DAPI). Immunos-
taining of the endothelial marker, CD31, was performed
with rat anti-mouse CD31 mAb (MEC 13.3; 1:50; BD
Biosciences) and HRP-linked goat anti-rat IgG F(ab′)2
fragment (1:200; Amersham ECL, GE Healthcare).
Microscopic images were acquired using an Axiovert
200 M equipped with an AxioCam and analyzed by
AxioVision software (Carl Zeiss).
Immunofluorescence staining
MCF-7, MCF-7-14 and MDA-MB-231 cells were plated
on coverslips and fixed with 4% paraformaldehyde/
phosphate-buffered saline (PBS) for 15 min and permea-
bilized with 0.1% Triton X-100 in PBS for 2 min, and
then incubated in PBS containing 5% skim milk for 1 h
at room temperature. Cells were incubated with anti-E-
cadherin (1:100), anti-b-catenin (8E7; 1:100; Upstate
Biotechnology/Millipore, Billerica, MA), anti-vimentin
(1:300) and anti-fibronectin (clone 10; 1:200; BD Bios-
ciences) mAbs for 1 h at room temperature, followed by
incubation with Alexa Fluor 488-conjugated goat anti-
mouse IgG (1:200-1:1000) and nuclear counterstaining
with DAPI.
RNA isolation
MCF-7, MCF-7-14 and MDA-MB-231 cells were syn-
chronized in S-phase with the thymidine-hydroxyurea
block method. Total RNA was isolated from cells
arrested in S-phase using an RNeasy Mini kit (Qiagen,
Hilden, Germany).
Microarray analysis
cDNA was synthesized from total RNA isolated from
MCF-7, MCF-7-14 and MDA-MB-231 cells using a
One-Cycle cDNA Synthesis Kit (Affymetrix, Santa Clara,
CA). In vitro transcription reactions were performed
using a GeneChip IVT Labeling Kit. Fifteen micrograms
of the labeled cRNA was hybridized to a Human Gen-
ome U133 Plus 2.0 Array (Affymetrix). The array images
were scanned and analyzed using Genechip operating
software (GCOS; Affymetrix). The full microarray data
set is available in the NCBI Gene Expression Omnibus
public database under data series accession number
GSE18903.
Microarray data analysis
Using GeneSpring GX 7.3.1 software (Agilent Technolo-
gies, Santa Clara, CA), microarray data of each chip
were normalized to the 50
th percentile of the measure-
ments on that chip. For per-gene normalization, the
measurements of each probe were normalized to the
median of the measurements of that probe in MCF-7,
MCF-7-14 and MDA-MB-231 cell lines. Average linkage
hierarchical clustering was carried out on genes filtered
on detection flags ("present” in two or more cell lines)
and signal intensity (>50 in all cell lines). To identify
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isms regarding their invasive potential, genes up- or
down-regulated >2-fold in both MCF-7-14 and MDA-
MB-231 cells compared with MCF-7 cells were selected
from the filtered genes. Ingenuity Pathway Analysis soft-
ware (IPA 5.0; Ingenuity Systems, Redwood City, CA)
was also utilized to identify the top significant canonical
pathways for these selected genes and to functionally
link the most differentially expressed genes.
Quantitative real-time-PCR
cDNA was synthesized from 2 μgt o t a lR N Au s i n g
SuperScript III reverse transcriptase (Invitrogen).
Reverse transcription (RT) was run for 1 h at 50°C and
stopped by heating for 5 min at 85°C. PCR was con-
ducted in a 7900HT Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA). A 10 μlr e a c t i o n
containing 0.2 μlc D N A ,0 . 5μM of each primer and
2.5 μl Power SYBR Green PCR Master Mix (Applied
Biosystems) was used to monitor double-strand DNA
synthesis. Primer sequences are provided in Additional
file 1. Quantitative RT-PCR (qRT-PCR) was carried out
following the recommended thermal profile: 95°C for
10 min (pre-incubation) followed by 40 cycles of 95°C
for 15 sec (denaturation) and 60°C for 1 min (annealing
and elongation). Fluorescence intensity of the amplified
products was measured at the end of each PCR cycle.
Two runs were performed with each data point run in
triplicate. Results were normalized to internal control
GAPDH mRNA and if necessary, represented relative to
mRNA levels of MCF-7 cells.
Single-cell cloning
MCF-7 and MCF-7-14 cells were plated on 96-well
plates at a concentration of a single cell per well, which
was confirmed visually. Wells containing either none or
more than one cell were excluded from further analysis.
Single-cell clones were cultured to allow the growth of
individual colonies, which were picked and expanded in
culture, and analyzed by Matrigel invasion assay and
flow cytometry.
Flow cytometry
Three human breast cancer cell lines, MCF-7, MCF-7-
14 and MDA-MB-231, and single-cell clones derived
from the MCF-7 and MCF-7-14 cell lines were used in
flow cytometry analysis. Cells were harvested with Try-
pLE Express (Invitrogen), and then suspended (2 × 10
6
cells/100 μl) with Stain Buffer containing 1% FBS (BD
Biosciences). Phycoerythrin (PE)-conjugated mAbs
against human CD44 (G44-26; BD Biosciences) or CD24
(ML5; BD Biosciences) were added to the cell suspen-
sion at the concentrations recommended by the manu-
facturer and incubated at 4°C in the dark for 60 min.
The labeled cells were fixed in 100% methanol on ice
for 5 min. Flow cytometry analysis were performed in
triplicate using a FACSCalibur system (BD Biosciences).
Function-blocking antibody treatment
Cells (1 × 10
6 cells) were incubated with rat anti-human
CD44 mAb (IM7; BD Biosciences) or normal rat IgG at
400 μg/ml for 20 min. After preincubation, a cell prolif-
eration assay, cell migration assay and Matrigel invasion
assay were performed. Cell proliferation was assessed by
MTT assay. The cell migration assay was performed
using an Oris Cell Migration Assay (Platypus Technolo-
g i e s ,M a d i s o n ,W I ) ,w h i c hc o m p r i s e sa9 6 - w e l lp l a t e
with silicone stoppers (2 mm diameter) in each well.
Following cell seeding and cell attachment (2 × 10
4
cells), the stoppers were removed and migration pro-
ceeded for 72 h. Cells were then stained with crystal
violet and imaged through a microscope. Matrigel Inva-
sion Chambers (for a 24-well plate; BD Biosciences)
were used to examine cell invasion. Pretreated cells (5 ×
10
4 cells) in serum-free RPMI1640 were seeded into the
upper chamber and invading cells were fixed and
stained after 60 h cultivation.
Statistical analysis
Data are the means ± standard deviation (SD). Values
were compared between MCF-7 and MCF-7-14 cells
and between normal IgG and anti-CD44 mAb using
Student’s t test. Comparisons among cell lines were
made using analysis of variance (ANOVA) and Tukey-
Kramer multiple comparison, where appropriate. P <
0.05 was considered significant.
Results
Selection and morphological characterization of MCF-7-14
cells
MCF-7 cells were seeded into a Matrigel Invasion
Chamber. After 60 hours’ cultivation, cells that migrated
through the Matrigel membrane (MCF-7-1) were
harvested, proliferated on a dish, and then reseeded in a
Matrigel Invasion Chamber. Matrigel invasive cells are
rare populations within MCF-7 cells. Very few cells
migrated through the Matrigel until the 8
th cycle of
sequential selection (Figure 1A and 1B); however, after
the 9
th cycle, Matrigel invasive cells markedly increased,
and finally, through 14 cycles of sequential Matrigel
screening, we obtained MCF-7-14 cells with a signifi-
cantly (P < 0.01) higher proportion of invasive cells
than parental MCF-7 cells (Figure 1A and 1B). The
selected MCF-7-14 cells in culture were compared with
parental MCF-7 cells for morphology and proliferative
capacity. MCF-7-14 cells uniquely displayed anchorage-
independent growth and formed non-adherent spheres
(Figure 1C); however, the proliferative capacity of
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cells (Figure 1D). In addition, MCF-7-14 cells expressed
ER-a but not HER-2, similar to MCF-7 cells (Figure 1E).
Migratory and metastatic ability of MCF-7-14 cells
The migratory ability of MCF-7-14 cells was compared
with that of parental MCF-7 cells using an in vitro
wound healing assay. MCF-7-14 cells displayed signifi-
cantly more rapid wound closure at all time points
(Figure 2A and 2B), tending to protrude into the wound
site, compared with MCF-7 cells (Figure 2C). Using a
nude mouse orthotopic xenograft model, we assessed
the in vivo metastatic ability of MCF-7-14-EGFP cells
(Figure 3A). Distant metastases to the pancreas and
peritoneum became detectable by fluorescence imaging
4 weeks after implanting MCF-7-14-EGFP cells and
appeared in 20% of implanted animals (2/10), whereas
no metastatic lesions were detected in MCF-7-EGFP-
bearing animals (0/10). Metastasized MCF-7-14-EGFP
cells invaded the pancreatic parenchyma, as shown by
HE and MGP staining, and expressed EGFP (Figure 3B).
In another case, 12 weeks after implantation of MCF-7-
14-EGFP cells, pancreas metastasis showed strong stro-
mal and angiogenic responses closely intermingled with
metastasized tumor cells, as demonstrated by immunos-
taining for CD31 (Figure 3C).
Epithelial and mesenchymal marker expression in
MCF-7-14 cells
In immunohistochemistry, mammary xenografts and
pancreas metastases generated by MCF-7-14-EGFP cells
were positive for a luminal epithelial marker, CK 19,
Figure 1 In vitro sequential selection of invasive populations from MCF-7 cells using Matrigel Invasion Chambers.( Aa n dB )I ne a c h
cycle, cells invading the Matrigel were fixed with 10% formalin-neutralized buffer and stained with crystal violet on the underside of the
chamber (A), and then the numbers of invading cells were counted under a microscope (B). Data are the means ± SD (n = 3). Statistical analysis
was performed by Student’s t test. *, P < 0.01, compared with MCF-7 cells. (C) Images of morphology of MCF-7 and MCF-7-14 cells in culture.
MCF-7-14 cells were propagated as non-adherent spheres (arrow). (D) Proliferative rates of MCF-7 and MCF-7-14 cells. (E) Western blotting
analysis for the expression of HER-2 and ER-a in MCF-7 and MCF-7-14 cells.
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mesenchymal marker, vimentin, similarly to MCF-7-
EGFP xenografts (Figure 4A). To molecularly character-
ize MCF-7, MCF-7-14 and MDA-MB-231 cells in more
detail, we analyzed mRNA and protein expressions of
epithelial and mesenchymal markers related to EMT.
The mRNA expression levels of E-cadherin and
mesenchymal markers, N-cadherin and vimentin, were
similar between MCF-7 and MCF-7-14 cells, while they
confirmed that MDA-MB-231 cells had already under-
gone “complete EMT”, defined by loss of epithelial mar-
kers and gain of mesenchymal markers (Figure 4B).
Immunofluorescence analysis (Figure 4C) showed the
localization of E-cadherin in adherent cell-cell junctions
in both MCF-7 and MCF-7-14 cells, whereas E-cadherin
was not detectable in MDA-MB-231 cells. In MCF-7
cells, immunofluorescence staining of b-catenin was
strongly positive on the cell membrane, whereas in
MDA-MB-231 cells, b-catenin was mainly expressed in
Figure 2 Migratory abilities of MCF-7 and MCF-7-14 cells in
wound healing assay. (A) Optical microscopic images of in vitro
wound healing at 0, 24, 48, 72 and 96 h after the creation of
wounds. (B) Comparison of images to quantify the migration rate of
the cells. Wound distances were measured at each time point and
expressed as percent wound closure by comparing the zero time.
Data are the means ± SD (n = 3). Statistical analysis was performed
by Student’s t test. *, P < 0.05; P < 0.01, compared with MCF-7. (C)
Optical microscopic images of MCF-7 and MCF-7-14 cells at the
invading edges of the wound at 48 h after the creation of wounds.
Figure 3 Metastatic abilities of MCF-7 and MCF-7-14 cells in
mouse xenograft model.( A )In vivo scanning of EGFP-expressing
breast cancer cells in mice at 4 weeks after implantation into the
mammary fat pad. In an MCF-7-14-EGFP-bearing mouse, metastasis to
the pancreas (arrowhead) was imaged, corresponding to the photo of
the abdomen. (B) EGFP-positive region in panel A was analyzed by HE
and MGP staining, or unstained sections were analyzed for EGFP
fluorescence. Metastasized MCF-7-14-EGFP cells (M) invaded pancreatic
parenchyma (P). (C) Representative pancreas metastasis 12 weeks after
implantation of MCF7-14-EGFP cells. Pancreas metastasis showed
strong stromal (S) and angiogenic responses (brown) closely
intermingled with metastasized tumor cells (M).
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only on the cell membrane but also in the nucleus in
MCF-7-14 cells. Immunofluorescence staining for
vimentin and fibronectin demonstrated cytoplasmic
localization in MDA-MB-231 cells, although they were
detectable in neither MCF-7 nor MCF-7-14 cells.
144 unique genes differentially expressed in both
MCF-7-14 and MDA-MB-231 cells
To identify genes associated with the invasive phenotype
of breast cancer cells, we performed DNA microarray
analysis and compared gene expression profiles among
MCF-7, MCF-7-14 and MDA-MB-231 cells; 13,092
probe sets were detected in all samples. Hierarchical
clustering based on informative probe sets showed that
the MCF-7-14 cell gene expression profile was more
similar to that of MCF-7 cells than MDA-MB-231 cells;
however, there were some similarities between MCF-7-
14 and MDA-MB-231 cells in gene expression (Figure
5A). Regarding their invasive potential, we selected 163
probe sets corresponding to 144 unique genes upregu-
lated (76 probe sets, Additional file 2) or downregulated
(87 probe sets, Additional file 3) >2-fold in both MCF-
7-14 and MDA-MB-231 cellsc o m p a r e dw i t hM C F - 7
cells from the filtered genes (Figure 5B).
Top canonical pathways and functional networks for
differentially expressed genes
To assess the relevance of the 163 probe sets to pre-
viously defined signaling pathways, canonical pathway
analysis was performed using IPA 5.0. Table 1 shows
the top 16 signaling pathways for the selected genes.
Some of these signaling pathways were involved in regu-
lating cell migration and stem cell function. In this
Figure 4 Comparative analysis of epithelial and mesenchymal marker expression. (A) Immunostaining for CK19, E-cadherin and vimentin
(brown or green) was performed on mammary xenografts and pancreas metastases 4 or 12 weeks after implantation of MCF-7-EGFP and MCF-
7-14-EGFP cells. (B) qRT-PCR analysis of mRNA expression of E-cadherin, N-cadherin, and vimentin performed on RNA samples isolated from
MCF-7, MCF-7-14 and MDA-MB-231 cells. Results were normalized to internal control GAPDH mRNA. Data are the means ± SD (n = 3). Statistical
analysis was performed by ANOVA and Tukey-Kramer multiple comparison. *, P < 0.01, compared with MCF-7 cells. (C) Immunofluorescence
analysis of MCF-7, MCF-7-14 and MDA-MB-231 cells using anti-E-cadherin, anti-b-catenin, anti-vimentin and anti-fibronectin mAbs (green). Cells
were nuclear counterstained with DAPI (blue).
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canonical pathways were multiple-mapped genes
(9 genes, 74%; Table 1). Considering the general notion
that cancer metastasis is a result of multifactorial cross-
talk between different molecular pathways, we generated
significant functional association networks in invasive
cells (see Additional file 4). The network with the high-
est score (Figure 5C) was constructed relating to DNA
replication, recombination and repair, cell cycle, and
cancer. Of note, six multiple-mapped genes (PIK3R1,
SOCS2, BMP7, CXCL12, CD44 and TCF3; Table 1) were
mapped on the most significant network (Figure 5C).
These genes were thought to be highly associated with
the migratory and invasive phenotype.
Evaluation of selected interesting genes: CD44
upregulation and CD24 downregulation in MCF-7-14 cells
Selected interesting genes (PIK3R1, SOCS2, BMP7,
CXCL12, CD44 and CD24) were evaluated by qRT-PCR
using total RNA from MCF-7, MCF-7-14 and MDA-
MB-231 cells. The mRNA expression levels of SOCS2
and CD44 were significantly (P < 0.01) higher in both
MCF-7-14 and MDA-MB-231 cells than in MCF-7 cells.
In contrast, PIK3R1, BMP7 and CD24 were significantly
Figure 5 Microarray gene expression data mining: hierarchical clustering and functional network analysis. (A) Hierarchical clustering
analysis of gene expression profiles in MCF-7, MCF-7-14 and MDA-MB-231 cell lines. Columns represent the 13,092 probe sets detected in all
samples. Measurements of each probe were normalized to the median of the probe measurements in MCF-7, MCF-7-14 and MDA-MB-231 cell
lines. The intensity of bar colors indicates the degree of gene upregulation (red) or downregulation (green). Although the MCF-7-14 cell gene
expression profile was more similar to that of MCF-7 cells than to MDA-MB-231 cells, there were some similarities between MCF-7-14 and MDA-
MB-231 cells in gene expression (black flames). (B) To identify potentially important differences in biological mechanisms regarding their invasive
potential, we selected 163 probe sets up- (red, see Additional file 2) or downregulated (green, see Additional file 3) >2-fold in both MCF-7-14
and MDA-MB-231 cells compared with MCF-7 cells. Results are represented relative to mRNA levels of MCF-7 cells. (C) The most significant
network of 163 probe sets (144 unique genes) constructed using IPA 5.0 (see Additional file 4). Gene network is represented as nodes and lines
between two nodes. Node shapes symbolize the functional class of the gene product: square, cytokine; diamond, enzyme; inverted triangle,
kinase; rectangle, nuclear receptor; ellipse, transcription regulator; circle, other. The intensity of node colors indicates the degree of upregulation
(red) or downregulation (green). Continuous and dashed lines indicate direct and indirect interactions between molecules, respectively. Bold
nodes represent multiple-mapped genes (see also Table 1) or selected interesting genes.
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231 cells (Figure 6A); however, MCF-7-14 cells showed
a lower degree of upregulation or downregulation than
MDA-MB-231 cells. CXCL12 mRNA expression was
similar between MCF-7 and MCF-7-14 cells, although it
was significantly (P < 0.01) downregulated in MDA-MB-
231 cells. Furthermore, the protein expression levels of
CD44 and CD24 were analyzed by flow cytometry.
MCF-7 cells expressed low levels of CD44 and high
levels of CD24, whereas MDA-MB-231 cells expressed
high levels of CD44 and low levels of CD24 (Figure 6B),
consistent with the results of qRT-PCR; however, MCF-
7-14 cells showed similar levels of CD44 protein expres-
sion to MCF-7 cells (Figure 6B, left panel). Thus, single-
cell clones were obtained from MCF-7 and MCF-7-14
cells, and analyzed by Matrigel invasion assay and flow
cytometry. Single-cell clones derived from MCF-7-14
cells had varying invasive abilities (Figure 6C). The
highly invasive cell clone (MCF-7-14 CL6, Figure 6C)
displayed a higher expression of CD44 than MCF-7 and
its non-invasive clone cells (Figure 6B, left panel). CD24
protein was downregulated in both MCF-7-14 and CL6
cells, compared with MCF-7 and CL17 cells (Figure 6B,
right panel). Therefore, these results raise the possibility
that alterations in the expression levels of genes selected
by pathway and network analysis, including expression
patterns of CD44 and CD24, may be accompanied by
the acquisition of invasive potential in MCF-7-14 cells.
Effects of anti-CD44 antibody treatment on cell migration
and invasion
To clarify whether CD44 positively goes hand in hand
with increased invasiveness, we examined the effects of
anti-CD44 mAb on cell proliferation, migration and
invasion. In the cell proliferation assay in the absence of
antibodies (Figure 7A), whereas MCF-7-14, similar to
MCF-7 cells, reached a plateau after 72 h, MCF-7-14
CL6 cells did not show a plateau phase, but rather con-
tinued to grow at a higher growth rate than MCF-7 and
MCF-7-14 cells. On the other hand, MDA-MB-231 cells
showed slower growth, but reached the same level as
MCF-7 cells by the end of the assay. Despite the differ-
ences in the growth rate, preincubation with anti-CD44
mAb had no significant effect on cell proliferation in all
cell lines tested, compared with treatment with normal
IgG (Figure 7B). In the cell migration assay, MCF-7-14
and its clone CL6 cells migrated as a sheet, whereas
MDA-MB-231 cells migrated more rapidly and more
individually (Figure 7C). In addition to the difference in
the method of cell migration, the CD44 expression level
differs between these cells; nevertheless, anti-CD44-mAb
significantly (P < 0.01) decreased cell migration in both
MCF-7-14 and MCF-7-14 CL6 cells as well as MDA-
MB-231 cells (Figure 7C and 7D). Anti-CD44-mAb also
significantly (P < 0.01) inhibited cell invasion in these
cells, although MCF-7-14 CL6 cells had a significantly
higher number of invading cells than MCF-7-14 and
MDA-MB-231 cells, differently from the results of the
cell migration assay (Figure 7E and 7F).
Discussion
MCF-7-14 cells as a novel model for breast cancer
metastasis without requiring constitutive EMT
We obtained MCF-7-14 cells that had a significantly
higher proportion of invasive cells throughout the in vitro
sequential selection process, although parental MCF-7
cells had few Matrigel invasive cells. In addition, we
demonstrated that EGFP-labeled MCF-7-14 cells metasta-
sized to the pancreas and peritoneum in a xenograft
model. In mouse orthotopic xenograft models of breast
cancer, the pancreas seems to be a relatively common
metastatic site. When injected into the mammary fat pad
of nude mice, N-cadherin-expressing cells, but not control
MCF-7 cells, metastasized to the liver, pancreas, salivary
gland, omentum, lung, lymph nodes, and lumbar spinal
muscle [11]. Murine 4T1 mammary cancer cells (expres-
sing the pcDNA-Neo expression vector as a control; 4T1-
Neo cells) implanted into the axillary mammary gland of
BALB/c mice metastasized to the mesentery adjacent to
Table 1 Top signaling pathways for the 163 differentially
expressed probe sets in MCF-7-14 and MDA-MB-231 cells
Pathway
Gene mapped to canonical
pathways
JAK/STAT Signaling PIK3R1, SOCS2
Xenobiotic Metabolism Signaling ALDH3B2, MAOB, PIK3R1,
UGT1A6
Axonal Guidance Signaling BMP7, CFL2, CXCL12, PIK3R1,
SEMA6D
TGF-b Signaling BMP7, SMURF2
Acute Phase Response Signaling PIK3R1, SOCS2, TCF3
Leukocyte Extravasation Signaling CD44, CXCL12, PIK3R1
Neuregulin Signaling ERRFI1, PIK3R1
IGF-1 Signaling CYR61, PIK3R1
p53 Signaling PIK3R1, RPRM
LPS/IL-1 Mediated Inhibition of RXR
Function
ALDH3B2, MAOB, SLC27A2
Serotonin Receptor Signaling MAOB
Notch Signaling LFNG
Coagulation System F12
Cell Cycle: G2/M DNA Damage
Checkpoint Regulation
RPRM
EGF Signaling PIK3R1
Wnt/b-catenin Signaling CD44, TCF3
Pathway analysis was performed on 163 probe sets (144 unique genes) up- or
down-regulated >2-fold in both MCF-7-14 and MDA-MB-231 cells compared
with MCF-7 cells (see Additional files 2 and 3) using IPA 5.0. Genes in bold are
mapped to multiple top canonical pathways, and genes in bold italics are also
mapped on the most significant functional network for the 163 probe sets
(see also Figure 5C).
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Page 9 of 15Figure 6 mRNA and protein expression of selected interesting genes. (A) qRT-PCR analysis of mRNA expression of SOCS2, CD44, PIK3R1,
BMP7, CXCL12 and CD24 was performed on RNA from MCF-7, MCF-7-14 and MDA-MB-231 cells. Results were normalized to internal control
GAPDH mRNA and represented relative to mRNA levels of MCF-7 cells. Data are the means ± SD (n = 3). Statistical analysis was performed by
ANOVA and Tukey-Kramer multiple comparison.*, P < 0.01, compared with MCF-7 cells. (B) CD44 and CD24 proteins expressed on three human
breast cancer cell lines (MCF-7, MCF-7-14 and MDA-MB-231) and single-cell clones derived from MCF-7 and MCF-7-14 cell lines (highly invasive
MCF-7-14 CL6 and non-invasive MCF-7 CL17, panel C) were analyzed by flow cytometry. (C) Matrigel invasion assay of single-cell clones derived
from MCF-7 (CL17-20) and MCF-7-14 (CL1-8) cell lines. Cells invading Matrigel were stained with crystal violet on the underside of the chamber.
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Page 10 of 15Figure 7 Effects of anti-CD44 antibody treatment on cell proliferation, migration and invasion. (A) Proliferation rates of untreated cells in
culture. Data are the means ± SD (n = 3). Statistical analysis was performed by ANOVA and Tukey-Kramer multiple comparison. *, P < 0.01,
compared with MCF-7 cells. (B) Proliferation rates of normal rat IgG-treated and anti-CD44 antibody-treated cells. In each cell line, the number of
normal IgG-treated cells at 96 h was considered 100%. Data are the means ± SD (n = 3). (C) Optical microscopic images of cell migration assay
at 72 h after removal of the stopper. Cells were fixed and stained with crystal violet. (D) Cell migration rates were expressed as percent closure
of the open area by comparing the zero time. Data are the means ± SD (n = 6). Statistical analysis was performed by Student’s t test or ANOVA/
Tukey-Kramer multiple comparison, where appropriate. *, P < 0.01, compared with normal IgG-treated cells.
†, P < 0.01, compared with MCF-7.
#,
P < 0.01, compared with MCF-7-14 and its clone CL6. (E) Matrigel invasion assay of normal rat IgG-treated and anti-CD44 antibody-treated cells.
After 60 h cultivation, cells invading Matrigel were fixed and stained on the underside of the chamber. (F) The numbers of invading cells were
counted under a microscope. Data are the means ± SD (n = 3). Statistical analysis was performed by Student’s t test or ANOVA/Tukey-Kramer
multiple comparison, where appropriate. *, P < 0.01, compared with normal IgG-treated cells.
†, P < 0.01, compared with MCF-7.
#, P < 0.01,
compared with MCF-7-14 and MDA-MB-231.
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Page 11 of 15the pancreas [12]. Despite differences in invasive ability,
MCF-7-14 cells, similar to MCF-7 cells, expressed E-
cadherin, but neither vimentin nor fibronectin. In the cell
migration assay, MCF-7-14 and its clone CL6 cells moved
as a sheet, in contrast to the more individual movements
of mesenchymal MDA-MB-231 cells. Cell-sheet move-
ment is a typical feature of epithelial cells during embryo-
nic development and wound healing [13]; therefore,
MCF-7-14 cells may be a novel model for breast cancer
metastasis without requiring constitutive EMT. Complete
and constitutive EMT seems not to be required for breast
cancer metastasis [1,14,15]. In particular, Lou et al. [16]
reported that 4T1 cells, which express E-cadherin and
ZO-1, are migratory, invasive, and metastasize to multiple
sites, and that 4T1-derived (67NR) cells, which form pri-
mary tumors but fail to metastasize, express vimentin and
N-cadherin, but not E-cadherin. The metastatic ability of
breast cancer cells does not seem to strictly correlate with
the genotypic and phenotypic properties of EMT per se.
In addition, Tarin et al. [17] suggested that the fundamen-
tal premise that EMT occurs in real cancers is very much
in doubt because of the lack of convincing evidence for
the conversion of epithelial cells into mesenchymal cell
lineages in vivo; however, it is possible that MCF-7 and
MCF-7-14 cells can make transient EMT in vitro in a
reversible fashion. For example, estrogen treatment pro-
moted reversible EMT-like changes and collective motility
in ER-positive breast cancer cells [18]. The transitory
acquisition of mesenchymal characteristics could explain
the difficulty in observing EMT in cancer development.
Nuclear b-catenin expression and “metastable
phenoptype” in MCF-7-14 cells
On the other hand, loss of E-cadherin-b-catenin com-
plex is an important step in the progression of many
epithelial malignancies [19]. b-catenin has a dual role in
the EMT; it enhances cell-cell adhesion when bound to
cadherin complexes in adherens junctions and also func-
tions as a transcriptional coactivator upon entry into the
nucleus [20]. Nuclear import of b-catenin is another
important player in EMT [21,22]. Indeed, in MDA-MB-
231 cells, b-catenin was mainly located in the nucleus,
whereas in MCF-7 cells, b-catenin was mostly expressed
on the cell membrane. Nuclear b-catenin induces a gene
expression pattern favoring tumor invasion and pro-
ceeds with transition to the mesenchymal phenotype of
epithelial tumor cells [23]. In MCF-7-14 cells, b-catenin
was expressed not only on the cell membrane but also
in the nucleus; therefore, enhanced invasive potential of
MCF-7-14 cells may result from “incomplete” EMT,
altering some signaling pathways. Several studies [24,25]
have identified a hybrid cell showing both epithelial and
mesenchymal traits. These cells are referred to as a
“metastable phenotype” and distinguished from both
epithelial and mesenchymal cells by characteristics such
as residual E-cadherin, nuclear b-catenin and sheet
movement [13,26]. According to this categorization,
MCF-7-14 cells may be just in a “metastable” cell state.
Alterations in cell migration signaling in MCF-7-14 cells
Here we analyzed which signaling pathways are asso-
ciated with the enhanced migratory and invasive poten-
tial of MCF-7-14 cells. Canonical pathway analysis using
IPA 5.0 identified the top 16 signaling pathways for dif-
ferentially expressed genes in invasive cells. Some of
these signaling pathways are involved in regulating cell
migration. JAK/STAT (Janus kinase/signal transducer
and activator of transcription) signaling is necessary for
border cell migration in the Drosophila ovary, suggest-
ing its relevance to the progression of cancer [27]. Axon
guidance molecules and neuregulin signaling play criti-
cal roles in cancer cell invasion as well as in neuronal
migration [28,29]. In addition, leukocytes exhibit the
ability to sense and move in the direction of a chemoat-
tractant [30]. Acute-phase response signaling modifies
inflammatory responses, thereby contributing to leuko-
cyte extravasation [31]. Directed cell movement or
chemotaxis is exhibited during wound healing, angio-
genesis, embryonic development, immune function, and
during cancer cell metastasis [32]. Pathway and network
analysis also identified a set of interesting genes, includ-
ing PIK3R1, SOCS2 and BMP7. Philp et al. [33] reported
the presence of somatic mutations in PIK3R1,t h eg e n e
for the p85a regulatory subunit of phosphatidylinositol
3-kinase (PI3K), in primary human colon and ovarian
tumors and cancer cell lines, resulting in the constitutive
activation of PI3K. In addition, MCF-7-14 and MDA-
MB-231 cells displayed the upregulated expression of
SOCS2 and downregulated expression of BMP7 com-
pared with MCF-7 cells. JAK/STAT signaling is nega-
tively regulated by overexpression of SOCS proteins,
and SOCS2 interferes with the negative regulatory
effects of SOCS1 and SOCS3 [27,34]. SOCS2 was gener-
ally upregulated in primary breast tumors that devel-
oped bone metastasis [35]. On the other hand,
transforming growth factor beta (TGF-b) is a pro-onco-
gene in the later stages of tumorigenesis and appears to
contribute to metastasis [36,37]. BMP7 is an antagonist
of the TGF-b pathway and can inhibit osteolytic metas-
tasis attributable to prostate cancer [38]. Decreased
BMP7 expression during carcinogenesis in the human
breast contributes to the acquisition of a bone meta-
static phenotype [39]. PI3K, JAK/STAT and TGF-b sig-
naling play key roles in cell migration, and PIK3R1,
SOCS2 and BMP7 are regulatory molecules of these sig-
naling pathways, thereby possibly contributing to metas-
tasis development. Consequently, alterations in these
signaling pathways may explain the differences in
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Page 12 of 15migratory and invasive potential between MCF-7 and
MCF-7-14 cells, demonstrating the validity and useful-
ness of this comparative analysis.
Possible relevance of MCF-7-14 cells to cancer stem cells
Canonical pathway analysis identified xenobiotic meta-
bolism signaling as one of the top signaling pathways in
invasive cells. This signaling pathway is possibly respon-
sible for maintenance of the stem cell phenotype and
multidrug resistance in breast cancer cells [40]. In addi-
tion, some of the top signaling pathways (JAK/STAT,
TGF-b, epidermal growth factor and Wnt/b-catenin sig-
naling) overlapped the signaling pathways important for
cancer stem-like cells, identified between the MCF-7
side population (SP) and non-SP cells [41]. These signal-
ing pathways are involved in both tumorigenesis in can-
cer and self-renewal in embryonic stem cells [42].
Although there are no direct evidences yet, MCF-7-14
cells, which have been derived from rare cell popula-
tions with higher invasive ability within MCF-7 cells,
may be possibly relevant to cancer stem-like cells. MCF-
7-14 cells have similar morphological characteristics to
those of stem/progenitor or chemotherapy-resistant cells
isolated from MCF-7 cells. Cells grown as non-adherent
spherical clusters, which were isolated from breast can-
cer lesions or MCF-7, displayed stem/progenitor cell
properties [43]. MCF-7 cells that survived chemothera-
peutic treatment formed looser colonies in the mono-
layer, with cells at the borders tending to have more
protruding filopodia [44]. Furthermore, invasive popula-
tions seem to generate both invasive and non-invasive
populations resembling the cases seen in SP [45] and
tumorigenic CD44
+CD24
-/low cells [8] of breast tumor
cells, because the numbers of cells invading the Matrigel
were very low until the 8
th cycle of in vitro sequential
selection. Interestingly, MCF-7-14 cells displayed
increased expression of CD44 mRNA and downregu-
lated expression of CD24 mRNA and protein. Although
MCF-7-14 cells showed cell population heterogeneity in
invasiveness and CD44 protein expression, MCF-7-14-
derived clone MCF-7-14 CL6, which had a higher num-
ber of invading cells, displayed upregulation of CD44
and rapid and extended proliferation. However, there
are no overlapping genes between our results and the
gene signature identified by gene expression profiling of
CD44
+CD24
- breast cancer stem-like cells [46]; there-
fore, our findings should be validated in further studies,
for example, analysis of stem cell marker expression.
Nuclear b-catenin and CD44 upregulation characterize
invasive cell populations in breast cancer
Mani, Weinberg and colleagues [10] found that cells
that had undergone EMT exhibited CD44
high/CD24
low
expression, suggesting that the EMT might confer
malignant properties on breast tumor cells. Although
the EMT seems not to be an “all or nothing” event,
upregulation of CD44 and downregulation of CD24
seem to participate in the acquisition of invasive and
metastatic potential [47-49]. In this study, despite the
difference in CD44 expression, treatment with CD44
mAb (clone IM7), which induces CD44 shedding from
the cell surface [50], significantly decreased cell migra-
tion and invasion in MCF-7-14 and its clone CL6 cells
as well as MDA-MB-231 cells. Although CD44 expres-
sion seems to be correlated with mesenchymal marker
expression as well as with invasiveness, CD44 may be
one of the most important adhesion molecules facilitat-
ing cell invasion and metastasis [51]. Furthermore,
CD44 expression is, directly or indirectly, regulated by
the b-catenin/Tcf-4 signaling pathway, especially in the
colorectal cancer precursor lesions, suggesting a role for
CD44 in intestinal tumorigenesis [52,53]. Brabletz et al.
[21] reported that nuclear b-catenin accumulates in ded-
ifferentiated colorectal carcinoma cells at the tumor-host
interface, whereas a gradual loss of nuclear b-catenin is
seen towards central, well-differentiated areas of the
tumor. This heterogeneous pattern of the primary
tumor is recapitulated in corresponding liver metastases.
Nuclear accumulation of b-catenin in colorectal cancer
cells at the invasive front and in the vessels has been
suggested to be a powerful predictor of liver metastasis
[54]. In breast cancer, Wnt/b-catenin activation is an
important feature of basal-like breast cancers and is pre-
dictive of worse overall survival [55]. Consequently,
nuclear b-catenin and upregulation of CD44 may be
potential diagnostic and therapeutic targets for breast
cancer metastasis.
Conclusions
Although the MCF-7 cell line has a luminal epithelial-
like phenotype and lacks a CD44
+/CD24
- subpopulation,
we obtained MCF-7-14 cells of opposite migratory and
invasive capabilities from MCF-7 cells and developed a
novel model for breast cancer metastasis without requir-
ing constitutive EMT. This study better characterizes
invasive breast cancer cells and provides insight into
understanding the biology of breast cancer metastasis.
In clinical diagnosis, ER-positive, HER2-negative breast
cancer, which is defined as “luminal A” by the specific
expression of an intrinsic set of genes [56], is the most
common type of breast cancer and tends to have a bet-
ter prognosis than the other three types (luminal B,
HER-2 overexpressing, basal-like). However, the clinical
behavior of luminal-type breast cancer can be markedly
heterogeneous despite similar levels of ER expression
[57]; therefore, a set of genes differentially regulated in
MCF-7-14 cells (PIK3R1, SOCS2, BMP7, CD44 and
CD24) may be useful markers to identify among good
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Page 13 of 15prognosis tumors those that will relapse and metasta-
size. MCF-7-14 cells, in particular, showed nuclear
b-catenin expression and a similar phenotype to “meta-
stable” cells, which are distinguished from both epithe-
lial and mesenchymal cells [13]. In addition, MCF-7-14
and its invasive clone CL6 cells displayed increased
expression of CD44 and downregulated expression of
CD24 compared with MCF-7 cells. The alterations and
characteristics of MCF-7-14 cells may characterize inva-
sive cell populations in breast cancer.
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